WO1998056719A3 - Control standards for clinical chemistry assays - Google Patents

Control standards for clinical chemistry assays Download PDF

Info

Publication number
WO1998056719A3
WO1998056719A3 PCT/US1998/010513 US9810513W WO9856719A3 WO 1998056719 A3 WO1998056719 A3 WO 1998056719A3 US 9810513 W US9810513 W US 9810513W WO 9856719 A3 WO9856719 A3 WO 9856719A3
Authority
WO
WIPO (PCT)
Prior art keywords
clinical chemistry
chemistry assays
control standards
composition
assays
Prior art date
Application number
PCT/US1998/010513
Other languages
French (fr)
Other versions
WO1998056719A2 (en
Inventor
Julie Peddicord
Douglas Kang
Douglas Clark
Angela Puia
Original Assignee
Medical Analysis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Analysis Inc filed Critical Medical Analysis Inc
Publication of WO1998056719A2 publication Critical patent/WO1998056719A2/en
Publication of WO1998056719A3 publication Critical patent/WO1998056719A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/90—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving iron binding capacity of blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
    • G01N2400/14—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar alpha-D-Glucans, i.e. having alpha 1,n (n=3,4,6) linkages between saccharide units, e.g. pullulan
    • G01N2400/18—Cyclodextrin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/80—Multi-analyte reference solutions containing cholesterol, glucose and the like
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Abstract

Stabilized compositions for use in clinical chemistry assays are disclosed. The composition is stable in the liquid form. The composition minimizes the use of human derived starting materials and uses recombinant thermophilic enzymes as a substitute for native enzymes commonly used in chemistry controls.
PCT/US1998/010513 1997-06-13 1998-05-21 Control standards for clinical chemistry assays WO1998056719A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87438397A 1997-06-13 1997-06-13
US08/874,383 1997-06-13

Publications (2)

Publication Number Publication Date
WO1998056719A2 WO1998056719A2 (en) 1998-12-17
WO1998056719A3 true WO1998056719A3 (en) 1999-07-01

Family

ID=25363617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/010513 WO1998056719A2 (en) 1997-06-13 1998-05-21 Control standards for clinical chemistry assays

Country Status (1)

Country Link
WO (1) WO1998056719A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102706818A (en) * 2012-06-05 2012-10-03 宁波美康生物科技股份有限公司 Enzymatic triglyceride measuring method and measuring reagent

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007008A (en) * 1975-07-30 1977-02-08 Becker Milton J Preparation of reference serum from animal blood
US4121905A (en) * 1977-08-22 1978-10-24 Jonas Maurukas Process for preparing biological compositions for use as reference controls in diagnostic analyses
US4289649A (en) * 1978-09-11 1981-09-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Aqueous lipid standard solution
US4567150A (en) * 1981-11-20 1986-01-28 Sclavo, S.P.A. Method for determining transferrin and composition therefor
US4677075A (en) * 1986-05-05 1987-06-30 Louderback Allan Lee Urobilinogen control
EP0295009A2 (en) * 1987-06-03 1988-12-14 Baylor College Of Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
EP0337467A2 (en) * 1988-04-15 1989-10-18 Roche Diagnostics GmbH Method for the determination of thyroxine and a standard solution therefore
US5028542A (en) * 1990-02-07 1991-07-02 Boehringer Mannheim Corporation Glucose measurement control reagent and method of making the same
WO1993022349A1 (en) * 1992-04-24 1993-11-11 The Institute For Human Genetics And Biochemistry NATURAL HUMAN IgM ANTIBODIES
US5547873A (en) * 1994-02-22 1996-08-20 Genzyme Corporation Compositions for stabilizing proteins for long term dry storage and methods of making and using the compositions
EP0763741A1 (en) * 1995-03-16 1997-03-19 Kyowa Medex Co., Ltd. Method of quantitating cholesterol in low-density lipoprotein
US5614414A (en) * 1995-03-30 1997-03-25 Streck Laboratories, Inc. Liquid lipoprotein control
US5770451A (en) * 1995-03-30 1998-06-23 Streck Laboratories, Inc. Liquid lipoprotein control

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007008A (en) * 1975-07-30 1977-02-08 Becker Milton J Preparation of reference serum from animal blood
US4121905A (en) * 1977-08-22 1978-10-24 Jonas Maurukas Process for preparing biological compositions for use as reference controls in diagnostic analyses
US4289649A (en) * 1978-09-11 1981-09-15 Merck Patent Gesellschaft Mit Beschrankter Haftung Aqueous lipid standard solution
US4567150A (en) * 1981-11-20 1986-01-28 Sclavo, S.P.A. Method for determining transferrin and composition therefor
US4677075A (en) * 1986-05-05 1987-06-30 Louderback Allan Lee Urobilinogen control
EP0295009A2 (en) * 1987-06-03 1988-12-14 Baylor College Of Medicine Lactoferrin as a dietary ingredient promoting the growth of the gastrointestinal tract
EP0337467A2 (en) * 1988-04-15 1989-10-18 Roche Diagnostics GmbH Method for the determination of thyroxine and a standard solution therefore
US5028542A (en) * 1990-02-07 1991-07-02 Boehringer Mannheim Corporation Glucose measurement control reagent and method of making the same
WO1993022349A1 (en) * 1992-04-24 1993-11-11 The Institute For Human Genetics And Biochemistry NATURAL HUMAN IgM ANTIBODIES
US5547873A (en) * 1994-02-22 1996-08-20 Genzyme Corporation Compositions for stabilizing proteins for long term dry storage and methods of making and using the compositions
EP0763741A1 (en) * 1995-03-16 1997-03-19 Kyowa Medex Co., Ltd. Method of quantitating cholesterol in low-density lipoprotein
US5614414A (en) * 1995-03-30 1997-03-25 Streck Laboratories, Inc. Liquid lipoprotein control
US5770451A (en) * 1995-03-30 1998-06-23 Streck Laboratories, Inc. Liquid lipoprotein control

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUSSON M -O ET AL: "IRON ACQUISITION BY HELICOBACTER PYLORI: IMPORTANCE OF HUMAN LACTOFERRIN", INFECTION AND IMMUNITY, vol. 61, no. 6, 1 June 1993 (1993-06-01), pages 2694 - 2697, XP000577086 *

Also Published As

Publication number Publication date
WO1998056719A2 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
IL180906A0 (en) Pharmaceutical compositions comprising chromium and biotin and such pharmaceutical composition for reducing hyperglycemia and stabilizing the level of serum glucose
AU2003204510A1 (en) Yeast cell surface display of proteins and uses thereof
MX9502034A (en) Stable, lyophilized formulation, comprising a protein and dispensing equipment.
IL142216A0 (en) A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
AU2271999A (en) Liquid composition with enhanced low temperature stability
PT1056883E (en) Yeast cell surface display of proteins and uses thereof
AU5229598A (en) Pharmaceutical, cosmetic composition with base of microbial culture mixed with an essential oil and an acid
AU2663197A (en) Modulation of mammalian telomerase by peptide nucleic acids
AU4351997A (en) Assays for regulators of mammalian telomerase expression
CA2314900A1 (en) Fibrin mixture and dispenser assembly
PL341426A1 (en) Radiotelephone with touch-type user's interfaces and its mode of operation
EP2258402A3 (en) Dried composition
EP0948905A3 (en) Enzyme preparations comprising transglutaminase and process for producing noodles
WO2002006457A3 (en) Novel lipase genes
AU1416499A (en) Novel molecules of the follistatin-related protein family and uses therefor
CA2330972A1 (en) Fully recombinant tissue sealant compositions
AU6345998A (en) Self-aggregating protein compositions and use as sealants
AU7352096A (en) Use of thioethers as antioxidant for peptides and proteins and compositions containing the thioethers
AU1690599A (en) Artificial nail composition
WO1998056719A3 (en) Control standards for clinical chemistry assays
AU3950799A (en) Genetically engineered yeast and mutants thereof for the efficient fermentation of lignocellulose hydrolysates
AU7126798A (en) Bipolar electrochemical connection of materials
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
AU7819898A (en) Box-dependent myc-interacting protein (bin1) compositions and uses therefor
WO2001009373A3 (en) NATIVE Cdc25 SUBSTRATES, COMPOSITIONS AND USES RELATED THERETO

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CN JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CN JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999502512

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase